BioSpace News Archive

Revenues up 26%, operating profit up 38%, net profit up 73%

Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), announced that the Company believes it remains on target to report top-line data from the global Phase 3 INSPIRE Trial with intravenous (IV) rigosertib in second-line, higher-risk MDS patients in the first half of 2020 following full enrollment and 288 death events.

Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Wednesday, November 13, 2019, it will release third quarter 2019 financial results and host a conference call at 5:00 p.m. Eastern Standard Time / 2:00 p.m. Pacific Standard Time to discuss the financial results and recent business developments.

Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company’s supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP)

Scientist.com announced that its COMPLi® solution has expanded to include Animal Welfare as part of its ongoing effort to ensure that any non-human animals involved in scientific research are handled ethically and humanely.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present third quarter 2019 results and operational highlights in a conference call on October 31, 2019 at 8 a.m. ET.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular or “wet” age-related macular degeneration (wet AMD).

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2019 financial results will be released on Friday, November 1, 2019 before the U.S. financial markets open.

Oral presentations by Jill Waibel, MD and Ashish Bhatia, MD

Citius Pharmaceuticals, Inc. announced that the Company will present at the 5th Annual Dawson James Small Cap Growth Conference on Tuesday, Oct 29, 2019 at 4:30-4:50 PM ET in Track 2 - Preserve Ballroom B. The conference is being held at the Wyndham Grand Hotel in Jupiter, Florida on October 28-29, 2019..